Pharmacokinetics and Pharmacodynamics of Biotech Drugs

Derendorf, Hartmut

doi:10.1002/3527600906.mcb.200400105

Cited by 3 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…injection of 67 GaCl 3 ; they also report constant values (about 5% ID/g) of kidney concentration of the free radionuclide during the following two hours after injection (no values were reported after 2 h). In contrast, it has been reported that nimotuzumab is not directly excreted in the urine or metabolized by the microsomal hepatic system, maybe as result of its high molecular weight (150,000 kDa) [48,50,51]. The elimination route of antibodies has not been totally elucidated but several mechanisms have been proposed; for example, proteolysis in the liver and reticuloendothelial systems could result in the fractionation of the antibody into peptides and amino acids, which can be reused for the synthesis of new proteins or excreted in urine.…”

Section: Discussionmentioning

confidence: 99%

“…The elimination route of antibodies has not been totally elucidated but several mechanisms have been proposed; for example, proteolysis in the liver and reticuloendothelial systems could result in the fractionation of the antibody into peptides and amino acids, which can be reused for the synthesis of new proteins or excreted in urine. Furthermore, target elimination and nonspecific endocytosis have also been proposed [48,50,51].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft

et al. 2018

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on surgical resection, chemotherapy and/or radiation, has shown some benefits. However, the survival rate remains low. Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM. The aim of this research was to implement a procedure for nimotuzumab radiolabeling to evaluate its biodistribution and affinity for EGF (epidermal growth factor) receptors present in a mesothelioma xenograft. Nimotuzumab was radiolabeled with 67Ga; radiolabel efficiency, radiochemical purity, serum stability, and biodistribution were evaluated. Biodistribution and tumor uptake imaging studies by microSPECT/CT in mesothelioma xenografts revealed constant nimotuzumab uptake at the tumor site during the first 48 h after drug administration. In vivo studies using MPM xenografts showed a significant uptake of this radioimmunoconjugate, which illustrates its potential as a biomarker that could promote its theranostic use in patients with MPM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft

et al. 2018

View full text Add to dashboard Cite

show abstract

Preclinical and clinical safety of monoclonal antibodies

Tabrizi

Roskos

2007

Drug Discovery Today

View full text Add to dashboard Cite

Modeling drug-protein dynamics

Peletier¹

2012

Discrete &Amp; Continuous Dynamical Systems - S

View full text Add to dashboard Cite

In this paper we discuss two models involving protein binding. The first model describes a system involving a drug, a receptor and a protein, and the question is to what extent the affinity of the drug to the protein affects the drug-receptor binding and thereby the efficiency of the drug. The second model is the basic model underlying Target-Mediated Drug Disposition, which describes the pharmacokinetics of a drug in the presence of a target, often a receptor.2000 Mathematics Subject Classification. Primary: 34C20, 34D15; Secondary: 92C42, 92C45, 80A30.

show abstract

Pharmacokinetics and Pharmacodynamics of Biotech Drugs

Cited by 3 publications

References 57 publications

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft

Preclinical and clinical safety of monoclonal antibodies

Modeling drug-protein dynamics

Contact Info

Product

Resources

About